ClinicalTrials.gg
CompletedNCT03198130Updated Mar 19, 2020

An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1)

A Phase 1 interventional study of REGN2810 in Recurrent Squamous Cell Carcinoma of Head, Recurrent Squamous Cell Carcinoma of Neck and Metastatic Squamous Cell Carcinoma of Head, sponsored by Regeneron Pharmaceuticals. Completed at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-19.

Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2019, 7 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study is being conducted to compare the relationship of patient response to treatment to changes in tumor microenvironment.

02

Conditions studied

  • Recurrent Squamous Cell Carcinoma of Head
  • Recurrent Squamous Cell Carcinoma of Neck
  • Metastatic Squamous Cell Carcinoma of Head
  • Metastatic Squamous Cell Carcinoma Neck
03

In context

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. confirmed diagnosis of recurrent and/or SCCHN (squamous cell carcinoma of the head and neck) with no curative options with at least 1 lesion that is measurable by (RECIST) 1.1 criteria and accessible for . Primary tumor sites of oral cavity, oropharynx, larynx, or hypopharynx are included.
  2. Have failed/are to at least chemotherapy OR deemed unsuitable candidate for first line chemotherapy due to medical co-morbidities or patient preference
  3. (ECOG) performance status (PS) of 0 or 1
  4. Adequate hepatic function
  5. Adequate renal function
  6. Adequate bone marrow function
  7. Provide signed
  8. Willing and able to comply with clinic visits and study-related procedures

Key Exclusion Criteria:

  1. Ongoing or recent (within 5 years) evidence of significant disease that required treatment with systemic treatments, which may suggest risk for immune-related adverse event (irAEs)
  2. Prior treatment with an agent that blocks the programmed death-1/programmed death-ligand 1 (/PD-L1) pathway
  3. Prior treatment with other immune modulating anti-cancer agents
  4. Untreated or active or spinal cord compression
  5. Immunosuppressive doses within 4 weeks prior to the first dose of REGN2810
  6. Prior treatment with idelalisib

Other protocol-defined inclusion/exclusion criteria will apply

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    REGN2810

    REGN2810 administered IV over a 30 minute infusion

    Drug: REGN2810

Interventions

  • Intravenous (IV) use

    Also known as: cemiplimab, Libtayo

06

What researchers measure

Primary outcomes

  1. Correlation between changes in the tumor microenvironment and the change in tumor volume following REGN2810 treatment versus baseline.

    Time frame: At baseline and during REGN2810 treatment up to week 24

Secondary outcomes

  1. Correlation between baseline tumor characteristics and the change in tumor volume following REGN2810 treatment

    Time frame: At baseline and during REGN2810 treatment up to week 24

  2. Number of participants with treatment-related adverse events

    Time frame: Up to 54 weeks

  3. Concentrations of REGN2810 in serum

    Time frame: Up to 54 weeks

  4. Anti-REGN2810 antibody levels

    Time frame: Up to 54 weeks

  5. The overall response rate (ORR) in patients treated with REGN2810

    Time frame: Up to 54 weeks

  6. The progression-free survival (PFS) in patients treated with REGN2810

    Time frame: Up to 54 weeks

07

Study locations

6 sites
  • Seoul National University
    Seoul, 03080, Korea, Republic of
  • Yonsei University College of Medicine, Severence Hospital
    Seoul, 03722, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • University Birmingham
    Birmingham, United Kingdom
  • Guy's and St. Thomas' NHS Foundation Trust
    London, United Kingdom
  • Royal Cancer Hospital
    London, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2017 to primary completion in Jun 2019, 23 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2017
First posted
Jun 23, 2017
StartActual
Jul 3, 2017
Primary completionActual
Jun 27, 2019
CompletionActual
Feb 21, 2020
Last update
Mar 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03198130
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Jun 23, 2017
Start date
Jul 3, 2017
Primary completion
Jun 27, 2019
Completion
Feb 21, 2020
Last update
Mar 19, 2020

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cemiplimab

Start the discussion